An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)- associated acute lower respiratory infections in children

Nair, Harish; Verma, Vasundhara R.; Theodoratou, Evropi; Zgaga, Lina; Huda, Tanvir; Simões, Eric A. F.; Wright, Peter F.; Rudan, Igor; Campbell, Harry
January 2011
BMC Public Health;2011 Supplement 3, Vol. 11 Issue Suppl 3, p1
Academic Journal
Background: Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization. Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered questions from the CHNRI framework and their "collective optimism" towards each criterion was documented on a scale from 0 to 100%. Results: In the case of candidate vaccines for active immunization of infants against RSV, the experts expressed very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers; and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a maximum of about 10%.


Related Articles

  • Molecular Analysis of Respiratory Syncytial Virus Reinfections in Infants from Coastal Kenya. Scott, Paul D.; Ochola, Rachel; Ngama, Mwanajuma; Okiro, Emelda A.; James Nokes, D.; Medley, Graham F.; Cane, Patricia A. // Journal of Infectious Diseases;1/1/2006, Vol. 193 Issue 1, p59 

    Background. Individuals are reinfected with respiratory syncytial virus (RSV) repeatedly. The nature of reinfection, in relation to RSV genetic and antigenic diversity, is ill defined and has implications for persistence and vaccine control. Methods. We examined the molecular relatedness of RSV...

  • The pathogenesis of respiratory syncytial virus disease in childhood. McNamara, Paul S.; Smyth, Rosalind L. // British Medical Bulletin;Mar2002, Vol. 61 Issue 1, p13 

    Respiratory syncytial virus (RSV) is a leading cause of severe respiratory infection in infants and children. RSV is an RNA virus whose genome encodes 10 proteins. The G protein is responsible for viral attachment to cells whilst the F protein promotes syncytia formation. These proteins are also...

  • Human Metapneumovirus: A New Player among Respiratory Viruses. Boivin, Guy; Hamelin, Marie-Ève; Abed, Yacine // Clinical Infectious Diseases;4/1/2004, Vol. 38 Issue 7, p983 

    The human metapneumovirus (hMPV) is a newly described member of the Paramyxoviridae family belonging to the Me-tapneumovirus genus. Since its initial description in 2001, hemp has been reported in most parts of the world and isolated from the respiratory tract of subjects from all age groups....

  • Brief Report: Respiratory Syncytial Virus Activity—United States, 2003-2004.  // JAMA: Journal of the American Medical Association;3/9/2005, Vol. 293 Issue 10, p1186 

    Presents a report that summarizes trends in respiratory syncytial virus (RSV) activity reported to the National Respiratory and Enteric Virus Surveillance System during July 2003--June 2004. Description of the report; How RSV causes severe disease among older adults and persons of all ages with...

  • Lower Respiratory Tract Illness in the First Two Years of Life: Epidemiologic Patterns and Costs in a Suburban Pediatric Practice. McConnochie, Kenneth M.; Hall, Caroline B.; Barker, William H. // American Journal of Public Health;Jan1988, Vol. 78 Issue 1, p34 

    Abstract: The epidemiologic patterns and the economic impact of acute lower respiratory tract illness (LRTI) in children under age two were studied using data collected from November 1, 1971-August 30, 1975 in a suburban pediatric practice in Monroe County, New York. LRTI was responsible for 23...

  • Diagnostic utility of BINAX NOW RSV -- an evaluation of the diagnostic performance of BINAX NOW RSV in comparison with cell culture and direct immunofluorescence. Jonathan, Nteimam // Annals of Clinical Microbiology & Antimicrobials;2006, Vol. 5, p13 

    Background: The regular increase in the incidence of respiratory illness caused by respiratory syncytial virus (RSV) during winter months in the United Kingdom, and other countries with temperate climate is usually accompanied by increased bed pressures especially in paediatric units in these...

  • Respiratory Syncytial Virus and Parainfluenza Virus. Hall, Caroline Breese // New England Journal of Medicine;06/21/2001, Vol. 344 Issue 25, p1917 

    Focuses on respiratory syncytial virus (RSV) and parainfluenza virus. Classification and structure; Epidemiologic features; Pathogenesis; Effect of disease in children and adults; Reinfections in previously healthy persons; Immunity; Diagnosis; Prospects for immunization; Prophylaxis with immune...

  • Respiratory Syncytial Virus Infections. Marks, Melvin I. // Clinical Pediatrics;Nov1992, Vol. 31 Issue 11, p688 

    The article informs that respiratory syncytial virus (RSV) is the most common cause of serious respiratory infection in infants and children in North America. Two major groups and nine subgroups of the virus have been identified thus far. It is estimated that in the United States 100,000...

  • The Need for Validation of Statistical Methods for Estimating Respiratory Virus—Attributable Hospitalization. Gilca, Rodica; De Serres, Gaston; Skowronski, Danuta; Boivin, Guy; Buckeridge, David L. // American Journal of Epidemiology;Oct2009, Vol. 170 Issue 7, p925 

    Public policy regarding influenza has been based largely on the burden of hospitalization estimated through ecologic studies applying increasingly sophisticated statistical methods to administrative databases. None are known to have been validated by observational studies. The authors...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics